Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05909709 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain
A Phase 1 study of Back Pain and Facet Joint Pain, sponsored by Alimorad Farshchian.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05909709 is a Phase 1 study of Back Pain and Facet Joint Pain that is actively recruiting participants, run by Alimorad Farshchian. The registered enrollment target is 15 participants, below the 142-participant average among 37 other Back Pain trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05909709, a Phase 1 study of Back Pain and Facet Joint Pain, is actively recruiting participants, sponsored by Alimorad Farshchian.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic cells) will be safe, well tolerated, and whether it causes any side effects. The study will also examine if the use of the Investigational Product (IP) is able to reduce local inflammation or alleviate Facetogenic back pain
Conditions Studied
Interventions
- DRUG Alocyte low dose
- DRUG Alocyte medium dose
- DRUG Alocyte high dose
Study Locations (1)
Florida
- The Center for Regenerative Medicine - North Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05909709
The ClinicalTrials.gov registry entry for NCT05909709 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 37 other Back Pain trials with a reported enrollment target (89% lower). The listed sponsor is Alimorad Farshchian, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Back Pain appearing as the primary indexed condition, and to 3 interventions - of which Alocyte low dose is the first listed.
NCT05909709 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05909709 about?
NCT05909709 is a clinical study titled "Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain". The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic cells) will be safe, well tolerated, and whether it causes any side effects. The study will also examine if the use of the Investigational Product (IP) is able to reduce local inflammation or alleviate Face...
What is the current status of trial NCT05909709?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-04-29. Estimated completion is 2026-10-01.
What conditions does trial NCT05909709 study?
This clinical trial studies the following conditions: Back Pain, Facet Joint Pain, Facet Joints; Degeneration.
What interventions are being tested in trial NCT05909709?
The interventions under investigation include: Alocyte low dose (DRUG), Alocyte medium dose (DRUG), Alocyte high dose (DRUG).
Who is sponsoring clinical trial NCT05909709?
This trial is sponsored by Alimorad Farshchian, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05909709 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Back Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
RECRUITING · Phase 3
-
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
RECRUITING · NA
-
Cannabidiol for Reduction of Brain Neuroinflammation
RECRUITING · Phase 2
-
CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial
RECRUITING · Phase 3
-
Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain
RECRUITING · NA
-
Partners4Pain & Wellbeing: A Randomized Trial of Community Supported Complementary and Integrative Health Self-management for Back Pain
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.